Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis-Reference-Cited by-同舟云学术

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis

Published:2018-10-01 Issue:10 Volume:75 Page:1246
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Andorra Magí¹,Nakamura Kunio²,Lampert Erika J.¹³,Pulido-Valdeolivas Irene¹,Zubizarreta Irati¹,Llufriu Sara¹,Martinez-Heras Eloy¹,Sola-Valls Nuria¹,Sepulveda María¹,Tercero-Uribe Ana¹,Blanco Yolanda¹,Saiz Albert¹,Villoslada Pablo¹⁴,Martinez-Lapiscina Elena H.¹

Affiliation:

1. Center of Neuroimmunology Department of Neurology, Hospital Clinic of Barcelona, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

2. Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio

3. Cleveland Clinic, Lerner College of Medicine, Cleveland, Ohio

4. Now with Genentech, Inc, South San Francisco, California

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Reference39 articles.

1. Optimizing treatment success in multiple sclerosis.;Ziemssen;J Neurol,2016

2. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?;Giovannoni;Mult Scler Relat Disord,2015

3. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.;Hauser;Neuron,2006

4. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis.;Tallantyre;Mult Scler,2010

5. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.;Martinez-Lapiscina;Lancet Neurol,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis;Neurology Neuroimmunology & Neuroinflammation;2024-11

2. Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage;Clinical Neurology and Neurosurgery;2024-07

3. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial;Multiple Sclerosis Journal;2024-03-12

4. Brain volume loss in Japanese patients with multiple sclerosis is present in the early to middle stage of the disease;Heliyon;2024-03

5. Identification and management of subclinical disease activity in early multiple sclerosis: a review;Journal of Neurology;2023-10-21